Use of RIT-Seq to Decode Antitrypanosomal Drug Efficacy and Resistance
Alsford, Eckert et al., Nature
A team led by investigators at the London School of Hygiene and Tropical Medicine this week reports its use of all five current human African trypanosomiasis drugs in a genome-scale RNA interference target sequencing screen in Trypanosoma brucei, which it says revealed the "transporters, organelles, enzymes and metabolic pathways that function to facilitate antitrypanosomal drug action." Taking this RIT-seq profiling approach, the team identified "both known drug importers and the only known pro-drug activator, and [linked] more than fifty additional genes to drug action," it writes.
Genomic Health to Launch NGS-based Somatic Cancer Mutation Detection Platform for Pharma Research
January 25, 2012
Foundation Medicine Highlights Actionable Data from First Patient Samples Analyzed on NGS Cancer Dx
January 25, 2012
Exclusive License to RAD51C Gene Could Lead to New Myriad Test for Breast, Ovarian Cancer Risk
January 25, 2012
Sequencing Study Suggests Potential New Treatments for ALL Subset with Poor Response
January 25, 2012
Avalere Predicts Genomic Medicine Interventions will be Subject of CMS National Coverage Decisions
January 25, 2012
Genomic Health Hopes Decision-Making Study Results Will Drive Colon Cancer Dx Adoption, Payment
January 25, 2012
MDx/CDx Focus: FDA Okays PML Risk Test for Tysabri; MDxHealth Gets CLIA Nod; NY Approves AssurRx Lab
January 25, 2012
Ventana's Growing Companion Dx Focus Mirrors Parent Roche's Investment in Personalized Rx
January 18, 2012
Q&A: Lawyer Jeff Gibbs Discusses Implications of Veterinary Drug Case on FDA's LDT, RUO Guidances
January 18, 2012